Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
This maintenance phase is all about keeping those benefits going
Digestive enzymes
GLP-1s enhance blood sugar control and other metabolic markers by stimulating the release of insulin, a hormone that regulates blood sugar, while suppressing the secretion of glucagon, a hormone that raises blood sugar
For people with T2D, a phase 2 trial with mazdutide (doses 3, 4.5 and 6 mg) has shown reduction in HbA1c (up to 1.7%) and up to 7.1% WL at 20 weeks (Table 3), while early phase trials for MASH are in progress [72]
The first true oral GLP-1 competitor, orforglipron (Eli Lilly, brand name Foundayo), is a non-peptide agonist expected to launch at a significantly lower price point
References: Step 1 Trial: Wilding, J.P.H., et al
US$ 25.02
US$ 27.51
US$ 29.66
US$ 27.05
